Combined methylphenidate and atomoxetine pharmacotherapy in attention deficit hyperactivity disorder

References

• Achenbach TM. 1991a. Manual for the Child Behavior Check List/4–18 and 1991 Profile. Burlington, VT: Department of Psychiatry, University of Vermont.
   Google Scholar
• Achenbach TM. 1991b. Manual for the Teacher Report Form and 1991 Profile. Burlington, VT: Department of Psychiatry, University of Vermont.
   Google Scholar
• American Psychiatric Association. 1994. Diagnostic and statistical manual of mental disorders. 4th ed. DSM-IV. Washington, DC.
   Google Scholar
• American Psychiatric Association. 2013. Diagnostic and statistical manual of mental disorders. 5th ed. DSM-V. Washington, DC.
   Google Scholar
• Brown, TE. 2004. Atomoxetine and stimulants in combination for treatment of attention deficit hyperactivity disorder: four case reports. J Child Adolesc Psychopharmacol 14(1):129–136.
   PubMed Web of Science ®Google Scholar
• Carlson GA, Dunn D, Kelsey D, Ruff D, Ball S, Ahrbecker L, et al. 2007. A pilot study for augmenting atomoxetine with methylphenidate: safety of concomitant therapy in children with attention-deficit/hyperactivity disorder. Child Adolesc Psychiatry Ment Health 1:10.
   PubMedGoogle Scholar
• Cheng JY, Chen RY, Ko JS, Ng EM. 2007. Efficacy and safety of atomoxetine for attention-deficit/hyperactivity disorder in children and adolescents-meta-analysis and meta-regression analysis. 194(2):197–209.
   Google Scholar
• Ercan ES, Amado S, Somer O. 2001. Development of a test battery for the assessment of attention deficit hyperactivity disorder [in Turkish]. Turk J Child Adolesc Psychiatry 8: 132–144.
   Google Scholar
• Gökler B, Unal F, Pehlivanturk B, Kültür EÇ, Akdemir D, Taner Y. 2004. Reliability and Validity of Schedule for affective disorders and schizophrenia for school age children – present and lifetime version – Turkish version (K-SASD-PL-T). Turk J Child Adolesc Mental Health 11:109–116.
   Google Scholar
• Kaufman J, Birmaher B, Brent DA, Rao U, Flynn C, Moreci P, et al. 1997. Schedule for affective disorders and schizophrenia for school-age children-present and lifetime version (K-SADS-PL): initial relaibility and validity data. J Am Acad Child Adolesc Psychiatry 36(7):980–988.
   PubMed Web of Science ®Google Scholar
• Martinez-Raga J, Knecht C, Szerman N, Martinez MI. 2013. Risk of serious cardiovascular problems with medications for attention-deficit hyperactivity disorder. CNS Drugs. 27(1):15–30.
   PubMed Web of Science ®Google Scholar
• National Institute of Mental Health. 1985. CGI (Clinic Global Impression) Scale. Psychopharmacol Bull 21:839–843.
   Web of Science ®Google Scholar
• Newcorn JH, Kratochvil CJ, Allen AJ, Casat CD, Ruff DD, Moore RJ. 2008. Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and differential response. Am J Psychiatry 165(6):721–730.
   PubMed Web of Science ®Google Scholar
• Pliszka SR, Crismon ML, Hughes CW, Corners CK, Emslie GJ, Jensen PS, et al. 2006. Texas Consensus Conference Panel on Pharmacotherapy of Childhood Attention Deficit Hyperactivity Disorder.The Texas Children's Medication Algorithm Project: revision of the algorithm for pharmacotherapy of attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 45(6):642–657.
   Web of Science ®Google Scholar
• Pottegård A, Bjerregaard BK, Glintborg D, Kortegaard LS, Hallas J, Moreno SI. 2013. The use of medication against attention deficit/hyperactivity disorder in Denmark: a drug use study from a patient perspective. Eur J Clin Pharmacol 69(3): 589–598.
   PubMed Web of Science ®Google Scholar
• Sonuga-Barke EJ, Coghill D, Wigal T, DeBacker M, Swanson J. 2009. Adverse reactions to methylphenidate treatment for attention-deficit/hyperactivity disorder: structure and associations with clinical characteristics and symptom control. J Child Adolesc Psychopharmacol 19(6):683–690.
   PubMed Web of Science ®Google Scholar
• Treuer T, Gau SS, Méndez L, Montgomery W, Monk JA, Altin M, et al. 2013. A systematic review of combination therapy with stimulants and atomoxetine for attention-deficit/hyperactivity disorder, including patient characteristics, treatment strategies, effectiveness, and tolerability. J Child Adolesc Psychopharmacol 23(3):179–193.
   PubMed Web of Science ®Google Scholar
• Turgay A. 1994. Disruptive behavior disorders child and adolescent screening and rating scales for children, adolescents, parents and teachers. West Bloomfield, MI: Integrative Therapy Institute Publication.
   Google Scholar
• Wechsler D. 1974. Manual for the Wechsler Intelligence Scale for Children Revised. New York: Psychological Corp.
   Google Scholar
• Wilens TE. 2006. Mechanism of action of agents used in attention-deficit/hyperactivity disorder. J Clin Psychiatry 8:32–38.
   Google Scholar
• Wilens TE, Hammerness P, Utzinger L, Schillinger M, Georgiopoulous A, Doyle RL, et al. 2009. An open study of adjunct OROS-methylphenidate in children and adolescents who are atomoxetine partial responders: I. Effectiveness. J Child Adolesc Psychopharmacol 19(5):485–492.
   PubMed Web of Science ®Google Scholar